A major contributing factor is the immunosuppressive tumor microenvironment (TME), wherein aberrant expression and regulation of immune checkpoint molecules like PD-L1 play pivotal roles in treatment failure and adverse outcomes (Kong et al., 2023). Here, CD274 is linked to neoplasm.